Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Hat Yai-90110, Thailand.
Department of Chemistry, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Hat Yai-90110, Thailand.
Curr Drug Saf. 2022;17(3):241-249. doi: 10.2174/157488631602211118122907.
Phenytoin is the most commonly reported aromatic Anti-Epileptic Drug (AED) to cause Cutaneous Adverse Drug Reactions (CADRs). Cutaneous adverse drug reactions may be immune or non-immune mediated. It has been observed that predisposition is multifactorial and that gene mutations alone cannot be the cause.
In this study, we investigated the patient, disease, and drug-related risk factors associated with phenytoin-induced cutaneous adverse drug reactions in South Indian epileptic patients.
This study was conducted as a single-center prospective case-control study over a period of 13 months. The Fisher's exact test and multivariate binary logistic regression analysis were used to test the association of single and multiple variables, respectively.
This study comprised 26 patients with phenytoin-induced cutaneous adverse drug reactions (PHT-CARDs) and 32 phenytoin-tolerant controls with a mean age of 40.60±18.15 and 36.21±14.71 years, respectively. Among 26 phenytoin-induced cutaneous adverse drug reactions, 76.92% cases were mild-moderate reactions and 23.07% were severe. The onset latency period of these reactions ranged from 7-42 days. The multivariate analysis showed that multiple AEDs (OR =18.62, 95% CI 4.28-80.87, p=< .001) and comorbidities (OR= 5.98, 95% CI 1.33-26.78, p=.01) are risk factors for PHT-CADRs. PHT-SCARs were shown to be associated with previous allergy history (OR= 31, % CI 2.40-398.8, p=.008).
The risk factors found to be associated with CARDs in South Indian Epileptic patients are multiple AEDs, comorbidities, and past allergic history. Therefore, physicians and other associated health care professionals should closely monitor the patients when phenytoin is employed.
苯妥英是最常见的芳香族抗癫痫药物(AED),可引起皮肤不良反应(CADR)。皮肤不良反应可能是免疫或非免疫介导的。已经观察到易感性是多因素的,基因突变本身不能成为原因。
在这项研究中,我们调查了南印度癫痫患者中与苯妥英诱导的皮肤不良反应相关的患者、疾病和药物相关危险因素。
这项研究是在 13 个月的时间内作为一项单中心前瞻性病例对照研究进行的。Fisher 确切检验和多变量二项逻辑回归分析分别用于检验单变量和多变量的相关性。
这项研究包括 26 例苯妥英诱导的皮肤不良反应(PHT-CARDs)患者和 32 例苯妥英耐受对照患者,平均年龄分别为 40.60±18.15 岁和 36.21±14.71 岁。在 26 例苯妥英诱导的皮肤不良反应中,76.92%的病例为轻度至中度反应,23.07%为重度反应。这些反应的潜伏期从 7-42 天不等。多变量分析显示,多种 AED(OR=18.62,95%CI 4.28-80.87,p=<.001)和合并症(OR=5.98,95%CI 1.33-26.78,p=.01)是 PHT-CADRs 的危险因素。PHT-SCARs 与既往过敏史相关(OR=31,%CI 2.40-398.8,p=.008)。
与南印度癫痫患者 CARDs 相关的危险因素是多种 AED、合并症和既往过敏史。因此,当使用苯妥英时,医生和其他相关医疗保健专业人员应密切监测患者。